ArchPoint Investors’s Neurocrine Biosciences NBIX Stock Holding History

ArchPoint Investors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-41,021	Closed	-$3.99M	–	86
2021 Q1	$3.99M	Hold	41,021	–	–	1.13%	19
2020 Q4	$3.93M	Hold	41,021	–	–	1.09%	23
2020 Q3	$3.94M	Buy	41,021 +4,250	+12%	+$492K	1.26%	15
2020 Q2	$4.49M	Buy	36,771 +500	+1%	+$55.3K	1.44%	16
2020 Q1	$3.14M	Sell	36,271 -500	-1%	-$48.9K	1.24%	18
2019 Q4	$3.95M	Buy	36,771 +500	+1%	+$52.4K	1.21%	19
2019 Q3	$3.27M	Sell	36,271 -2,250	-6%	-$210K	1.11%	20
2019 Q2	$3.25M	Sell	38,521 -625	-2%	-$51.3K	1.03%	20
2019 Q1	$3.45M	Buy	39,146 +625	+2%	+$52.2K	1.03%	19
2018 Q4	$2.75M	Buy	38,521 +22,553	+141%	+$2.16M	0.95%	24
2018 Q3	$1.96M	Hold	15,968	–	–	0.53%	32
2018 Q2	$1.57M	Buy	+15,968	New	+$1.43M	0.45%	32

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

DCP

DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return

ArchPoint Investors's NBIX Position: Q2 2021 in Review

ArchPoint Investors sold out of Neurocrine Biosciences (NBIX) in Q2 2021, closing a stake of 41,021 shares — an estimated $3.99M sold.

ArchPoint Investors first reported a position in NBIX in Q2 2018 and held it in 12 quarters. The position peaked at $4.49M in Q2 2020. 409 funds tracked by Wall St. Rank hold NBIX as of Q2 2021.

ArchPoint Investors reported no remaining Neurocrine Biosciences position as of Q2 2021 after selling out during the quarter.
ArchPoint Investors sold 41,021 Neurocrine Biosciences shares in Q2 2021, an estimated $3.99M.
ArchPoint Investors first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 12 quarters.
ArchPoint Investors's Neurocrine Biosciences position peaked at $4.49M in Q2 2020.
409 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2021.

Based on ArchPoint Investors's 13F filing for Q2 2021, filed 13 Aug 2021.